News & Updates

In a prespecified secondary analysis of the phase III FLOW trial, semaglutide reduces the risk of serious infections and COVID-19 events in individuals with type 2 diabetes (T2D) and chronic kidney disease (CKD).

Anaemia affects nearly one in five patients hospitalized for acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and contributes to increased postdischarge mortality and readmission, a study has found. Its most common subtype is nutritional anaemia, followed by anaemia of chronic disease (ACD).

Therapeutic-dose anticoagulation has contributed to a decrease in the likelihood of organ support or death among noncritically ill hospitalized patients with COVID-19. Such experience shows how quick and rigorous approaches, when aligned, can promptly translate evidence into practice, suggests a study.